by Paul Krzyzanowski | Jun 6, 2013
GMO soybeans might have lessons for cell patents. Photo: Philip Dean via Flickr . At first glance, you wouldn’t think that a 76-year old soybean farmer from Indiana would have something in common with microbiologists, but Vernon Hugh Bowman brought back memories of my...
by David Kent | May 28, 2013
. A few weeks ago, Italian private company Stamina came under considerable pressure regarding their controversial use of mesenchymal stem cells in patients. The Italian government, it seems, had authorized an unproven stem cell therapy for use in patients. The...
by Lisa Willemse | May 24, 2013
Co-authored with Dr. Zubin Master, Assistant Professor at the Alden March Bioethics Institute, Albany Medical College and Research Associate at the University of Alberta’s Health Law and Science Policy Group. In the current discussion about the now controversial...
by Lisa Willemse | Apr 25, 2013
Co-authored with Geoff Lomax, CIRM’s Senior Officer to the Standards Working Group from the “Understanding Stem Cell Controversies” Workshop organized by the Stem Cell Network in Montreal. This article is cross-posted on the CIRM blog. The afternoon session on Day 2...
by Lisa Willemse | Apr 24, 2013
Co-authored with Geoff Lomax, CIRM’s Senior Officer to the Standards Working Group from the “Understanding Stem Cell Controversies” Workshop organized by the Stem Cell Network in Montreal. This article is cross-posted on the CIRM blog. “Stem cell...
by Nick Dragojlovic | Apr 23, 2013
. The U.S. Food and Drug Administration’s (FDA) ongoing efforts to assert its authority to regulate U.S.-based companies that offer unlicensed stem cell therapies (Regenerative Sciences or Celltex, for example) has prompted a mixed response from the regenerative...
Comments